vs
Equity Residential（EQR）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Equity Residential的季度营收约是Royalty Pharma plc的1.3倍（$781.9M vs $622.0M），Equity Residential净利率更高（48.9% vs 34.4%，领先14.4%），Royalty Pharma plc同比增速更快（4.8% vs 2.0%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs 3.4%）
Equity Residential是总部位于美国的公开上市房地产投资信托基金（REIT），核心业务聚焦公寓类不动产投资，在全美多地持有大量优质公寓资产，深耕租赁住房市场，拥有成熟的运营管理经验和突出的行业竞争优势。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
EQR vs RPRX — 直观对比
营收规模更大
EQR
是对方的1.3倍
$622.0M
营收增速更快
RPRX
高出2.8%
2.0%
净利率更高
EQR
高出14.4%
34.4%
两年增速更快
RPRX
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $781.9M | $622.0M |
| 净利润 | $382.1M | $214.2M |
| 毛利率 | — | — |
| 营业利润率 | 50.6% | 62.4% |
| 净利率 | 48.9% | 34.4% |
| 营收同比 | 2.0% | 4.8% |
| 净利润同比 | -8.8% | 2.9% |
| 每股收益（稀释后） | $1.01 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EQRRPRX
| Q4 25 | $781.9M | $622.0M | ||
| Q3 25 | $782.4M | $609.3M | ||
| Q2 25 | $768.8M | $578.7M | ||
| Q1 25 | $760.8M | $568.2M | ||
| Q4 24 | $766.8M | $593.6M | ||
| Q3 24 | $748.3M | $564.7M | ||
| Q2 24 | $734.2M | $537.3M | ||
| Q1 24 | $730.8M | $568.0M |
净利润EQRRPRX
| Q4 25 | $382.1M | $214.2M | ||
| Q3 25 | $289.1M | $288.2M | ||
| Q2 25 | $192.4M | $30.2M | ||
| Q1 25 | $256.6M | $238.3M | ||
| Q4 24 | $419.1M | $208.2M | ||
| Q3 24 | $143.4M | $544.0M | ||
| Q2 24 | $177.5M | $102.0M | ||
| Q1 24 | $295.8M | $4.8M |
营业利润率EQRRPRX
| Q4 25 | 50.6% | 62.4% | ||
| Q3 25 | 38.5% | 70.1% | ||
| Q2 25 | 26.6% | 36.3% | ||
| Q1 25 | 35.7% | 94.0% | ||
| Q4 24 | 57.2% | 60.9% | ||
| Q3 24 | 20.1% | — | ||
| Q2 24 | 25.3% | 50.2% | ||
| Q1 24 | 42.0% | -13.0% |
净利率EQRRPRX
| Q4 25 | 48.9% | 34.4% | ||
| Q3 25 | 36.9% | 47.3% | ||
| Q2 25 | 25.0% | 5.2% | ||
| Q1 25 | 33.7% | 41.9% | ||
| Q4 24 | 54.7% | 35.1% | ||
| Q3 24 | 19.2% | 96.3% | ||
| Q2 24 | 24.2% | 19.0% | ||
| Q1 24 | 40.5% | 0.8% |
每股收益（稀释后）EQRRPRX
| Q4 25 | $1.01 | $0.49 | ||
| Q3 25 | $0.76 | $0.67 | ||
| Q2 25 | $0.50 | $0.07 | ||
| Q1 25 | $0.67 | $0.55 | ||
| Q4 24 | $1.10 | $0.46 | ||
| Q3 24 | $0.38 | $1.21 | ||
| Q2 24 | $0.47 | $0.23 | ||
| Q1 24 | $0.77 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $55.9M | $618.7M |
| 总债务越低越好 | $8.2B | $9.0B |
| 股东权益账面价值 | $11.0B | $9.7B |
| 总资产 | $20.7B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.75× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资EQRRPRX
| Q4 25 | $55.9M | $618.7M | ||
| Q3 25 | $93.1M | $938.9M | ||
| Q2 25 | $31.3M | $631.9M | ||
| Q1 25 | $39.8M | $1.1B | ||
| Q4 24 | $62.3M | $929.0M | ||
| Q3 24 | $28.6M | $950.1M | ||
| Q2 24 | $38.3M | $1.8B | ||
| Q1 24 | $44.5M | $843.0M |
总债务EQRRPRX
| Q4 25 | $8.2B | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $8.2B | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益EQRRPRX
| Q4 25 | $11.0B | $9.7B | ||
| Q3 25 | $11.1B | $9.6B | ||
| Q2 25 | $11.0B | $9.5B | ||
| Q1 25 | $11.0B | $9.8B | ||
| Q4 24 | $11.0B | $10.3B | ||
| Q3 24 | $10.9B | $10.3B | ||
| Q2 24 | $11.0B | $9.8B | ||
| Q1 24 | $11.1B | $9.9B |
总资产EQRRPRX
| Q4 25 | $20.7B | $19.6B | ||
| Q3 25 | $21.1B | $19.3B | ||
| Q2 25 | $21.0B | $18.3B | ||
| Q1 25 | $20.6B | $17.6B | ||
| Q4 24 | $20.8B | $18.2B | ||
| Q3 24 | $20.9B | $18.0B | ||
| Q2 24 | $19.8B | $17.7B | ||
| Q1 24 | $19.9B | $16.1B |
负债/权益比EQRRPRX
| Q4 25 | 0.75× | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 0.74× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $387.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 1.01× | 3.86× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流EQRRPRX
| Q4 25 | $387.0M | $827.1M | ||
| Q3 25 | $476.7M | $702.6M | ||
| Q2 25 | $359.5M | $364.0M | ||
| Q1 25 | $425.5M | $596.1M | ||
| Q4 24 | $354.2M | $742.5M | ||
| Q3 24 | $401.4M | $703.6M | ||
| Q2 24 | $396.9M | $658.2M | ||
| Q1 24 | $421.0M | $664.6M |
现金转化率EQRRPRX
| Q4 25 | 1.01× | 3.86× | ||
| Q3 25 | 1.65× | 2.44× | ||
| Q2 25 | 1.87× | 12.06× | ||
| Q1 25 | 1.66× | 2.50× | ||
| Q4 24 | 0.85× | 3.57× | ||
| Q3 24 | 2.80× | 1.29× | ||
| Q2 24 | 2.24× | 6.45× | ||
| Q1 24 | 1.42× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EQR
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
